Inositol has behavioral effects with adaptation after chronic administration

Journal of Neural Transmission

Volumn 104, Issue 2-3, 1997, Pages 299-305

  Cohen, H ^a   Kotler, M ^a   Kaplan, Z ^a   Matar, M A ^a   Kofman, O ^a   Belmaker, R H ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Animal model; Anxiety; Inositol; PI cycle

Indexed keywords

INOSITOL; PSYCHOTROPIC AGENT;

ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; DEPRESSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SECOND MESSENGER;

EID: 0030909054     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01273190     Document Type: Article

References (32)

1. Arendrup K, Gregersen G, Hawley J, Hawthorne JN (1989) High-dose dietary myoinositol supplementation does not alter the ischemia phenomenon in human diabetics. Acta Neurol Scand 80: 99-102
2. Agam G, Shapiro J, Bersudsky Y, Kofman O, Belmaker RH (1994) High-dose peripheral inositol raises brain inositol levels and reverses behavioral effects of inositol depletion by lithium. Pharmacol Biochem Behav 49: 341-343
3. Baraban JM, Worley PF, Snyder SH (1989) Second messenger systems and psychoactive drug action: focus on the phosphoinositol system and lithium. Am J Psychiatry 146: 1251-1260
4. +. J Neurochem 65(5): 2279-2289
5. Belmaker RH, Bersudsky Y, Benjamin J, Agam G, Levine J, Kofman O (1995) Manipulation of inositol-linked second messenger systems as a therapeutic strategy in psychiatry. In: Gessa G, Fratta W, Pani L, Serra G (eds) Depression and mania. From neurobiology to treatment. Raven Press, New York
6. Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH (1995) Inositol treatment for panic disorder: a double-blind placebo-controlled crossover trial. Am J Psychiatry 152: 1081-1086
7. Bersudsky Y, Vinnitsky I, Grisaru N, Kofman O, Belmaker RH (1993) Dose-response and time-curve of inositol prevention of Li-pilocarpine seizures. Eur Neuropsychopharmacol 2 [Special issue]: 428-429
8. Cohen H, Bar-Haim N, Kotler M (1996) Acute inositol induces anxiety in rats. Biol Psychiatry 40: 426-427
9. Crawley JN (1994) Interactions between cholecystokinin and other neurotransmitter systems. In: Bradwejn J (ed) Cholecystokinin and anxiety. From neuron to behavior. Biomedical Publishers, CRC Press
10. File SE (1993) The interplay of learning and anxiety in the elevated plus maze. Behav Brain Res 58(1-2): 199-202
11. Fux M, Levine J, Aviv A, Belmaker RH (1966) Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 153: 1219-1221
12. Ghalayini A, Eichberg J (1985) Purification of phosphatidylinositol synthetase from rat brain by CDP-diacylglycerol affinity chromatography and properties of the purified enzyme. J Neurochem 44: 175-182
13. Greene DA, Brown MJ, Braunstein SN, Schwartz SS, Asbury AA, Winegrad AI (1981) Comparison of clinical course and sequential electrophysiological tests in diabetics with symptomatic polyneuropathy and its implications for clinical trials. Diabetes 30: 139-147
14. Hallman M (1984) Effect of extracellular myo-inositol on surfactant phospholipid synthesis in the fetal rabbit lung. Biochim Biophys Acta 795: 67-78
15. Hallman M, Jarvenpaa AL, Pohjavuori (1986) Respiratory distress syndrome and inositol supplementation in preterm infants. Arch Dis Childhood 61: 1076-1083
16. Hallman M, Bry K, Hoppu K, Lapp M, Pohjavuori M (1992) Inositol supplementation in premature infants with respiratory distress syndrome. N Engl J Med 326: 1233-1239
17. Jope RS, Williams MB (1994) Lithium and brain signal transduction systems. Biochem Pharmacol 47: 429-434
18. Kim J, Kyriazi H, Greene DA (1991) Normalization of NA+-K+-ATPase activity in isolated membrane fraction from sciatic nerves of streptozocin-induced diabetic rats by dietary myo-inositol supplementation in vivo or protein kinase C agonists in vitro. Diabetes 40: 558-567
19. Kofman O, Sherman WR, Katz V, Belmaker RH (1993) Restoration of brain myoinositol levels in rats increases latency to lithium-pilocarpine seizures. Psychopharmacology 110: 229-234
20. Kofman O, Belmaker RH (1993a) Biochemical, behavioral and clinical studies of the role of inositol in lithium treatment and depression. Biol Psychiatry 34: 839-852
21. Kofman O, Bersudsky Y, Vinnitsky I, Alpert C, Belmaker RH (1993b) The effect of peripheral inositol injection on rat motor activity models of depression. Israel J Med Sci 29: 580-586
22. Levine J, Goldberger I, Rapaport A, Schwarts M, Schilds C, Elizur A, Belmaker RH, Shapiro J, Agam G (1994) CSF inositol levels in schizophrenia are unchanged and inositol is not therapeutic in anergic schizophrenia. Eur Neuropsychopharmacol 4: 487-490
23. Levine J, Barak Y, Gonsalves M, Szor H, Elizur A, Kofman O, Belmaker RH (1995a) A double-blind controlled trial of inositol treatment of depression. Am J Psychiatry 152: 792-794
24. Levine J, Ring A, Barak Y, Elizur A, Belmaker RH (1995b) Inositol may worsen attention deficit disorder with hyperactivity. Hum Psychopharmacol 10: 481-484
25. Manji HK, Bersudsky B, Chen G, Belmaker RH, Potter WZ (1996) Modulation of protein kinase C isozymes and substrates by lithium: the role of myo-inositol. Neuropsychopharmacology 15: 370-381
26. Patishi Y, Lubrich B, Berge M, Kofman O, Van Calker D, Belmaker RH (1996) Differential uptake of myo-inositol in vivo into rat brain areas. Eur Neuropsychopharmacol 6: 73-75
27. 2) receptor induced homologous and heterologous desensitization. Brain Res 631: 349-351
28. Ramos RT, Gentil V, Gorenstein C (1993) Clomipramine and initial worsening in panic disorder: beyond the "jitteriness syndrome". J Psychopharmacol 7(3): 265-269
29. Reynolds JEF (1993) Martindale: the extra pharmacopoeia, 30th ed. The Pharmaceutical Press, London
30. Rodriguez SA, Martin MT, Fernandez E, Gonalons E (1994) Cecocolonic motility in the chicken. Effects of cholecystokinin. Life Sci 55(22): 1743-1755
31. Stout JC, Weiss JM (1994) An animal model for measuring behavioral responses to anxiogenic and anxiolytic manipulation. Pharmacol Biochem Behav 47(3): 459-465
32. Warsh JJ, Li PP (1996) Second messenger systems and mood disorders. Curr Opin Psychiatry 9: 23-29